BR112022016177A2 - Método de tratamento usando meta-arsenito - Google Patents

Método de tratamento usando meta-arsenito

Info

Publication number
BR112022016177A2
BR112022016177A2 BR112022016177A BR112022016177A BR112022016177A2 BR 112022016177 A2 BR112022016177 A2 BR 112022016177A2 BR 112022016177 A BR112022016177 A BR 112022016177A BR 112022016177 A BR112022016177 A BR 112022016177A BR 112022016177 A2 BR112022016177 A2 BR 112022016177A2
Authority
BR
Brazil
Prior art keywords
arsenite
meta
viral infection
treatment method
treating
Prior art date
Application number
BR112022016177A
Other languages
English (en)
Inventor
Yang Yong-Jin
Original Assignee
Komipharm Int Australia Pty Ltd
Panaphix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020900433A external-priority patent/AU2020900433A0/en
Application filed by Komipharm Int Australia Pty Ltd, Panaphix Inc filed Critical Komipharm Int Australia Pty Ltd
Publication of BR112022016177A2 publication Critical patent/BR112022016177A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Chemical Treatment Of Metals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

MÉTODO DE TRATAMENTO USANDO META-ARSENITO. A presente invenção se refere ao uso de meta-arsenito de sódio ou meta-arsenito de potássio em métodos para: a) reduzir uma resposta inflamatória devido a uma infecção viral, b) tratar ou prevenir uma condição inflamatória devido a uma infecção viral, ou c) tratar ou prevenir hipercitocinemia devido a uma infecção viral. A invenção também se refere a um método para tratar ou prevenir infecção viral em um indivíduo.
BR112022016177A 2020-02-16 2021-02-15 Método de tratamento usando meta-arsenito BR112022016177A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020900433A AU2020900433A0 (en) 2020-02-16 Method of treatment
AU2021900204A AU2021900204A0 (en) 2021-01-29 Method of treatment
PCT/AU2021/050128 WO2021159187A1 (en) 2020-02-16 2021-02-15 Method of treatment using meta-arsenite

Publications (1)

Publication Number Publication Date
BR112022016177A2 true BR112022016177A2 (pt) 2022-10-04

Family

ID=77291313

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022016177A BR112022016177A2 (pt) 2020-02-16 2021-02-15 Método de tratamento usando meta-arsenito

Country Status (14)

Country Link
US (1) US20230123135A1 (pt)
EP (1) EP4103200A4 (pt)
JP (1) JP2023513795A (pt)
KR (1) KR20230019811A (pt)
CN (1) CN115243692A (pt)
AU (1) AU2021219576A1 (pt)
BR (1) BR112022016177A2 (pt)
CA (1) CA3170519A1 (pt)
CL (1) CL2022002177A1 (pt)
IL (1) IL295648A (pt)
JO (1) JOP20220192A1 (pt)
MX (1) MX2022010066A (pt)
TW (1) TW202143985A (pt)
WO (1) WO2021159187A1 (pt)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063363A (en) * 1997-05-27 2000-05-16 Goodwin; Gary J Treatment for upper respiratory tract infections with potassium salts
TWI274585B (en) * 2002-06-03 2007-03-01 Nat Health Research Institutes Pharmaceutical composition, kit, and packaged product for treating infection by a flaviviridae virus
WO2006104292A1 (en) * 2005-03-31 2006-10-05 Komipharm International Co., Ltd. Pharmaceutical composition comprising arsenic acid, meta-arsenite, and pharmaceutically acceptable salts
EP1721615A1 (en) * 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US8945505B2 (en) * 2007-02-02 2015-02-03 Panaphix, Inc. Use of arsenic compounds for treatment of pain and inflammation
KR20090058423A (ko) * 2007-12-04 2009-06-09 심형섭 소디움 메타아르세나이트를 함유하는 ｃ형 바이러스성 간염치료용 조성물
MA52088A (fr) * 2018-03-22 2021-01-27 Komipharm Int Australia Pty Ltd Composition pharmaceutique comprenant du méta-arsénite et procédé de fabrication

Also Published As

Publication number Publication date
US20230123135A1 (en) 2023-04-20
CL2022002177A1 (es) 2023-04-10
JOP20220192A1 (ar) 2023-01-30
EP4103200A1 (en) 2022-12-21
CA3170519A1 (en) 2021-08-19
JP2023513795A (ja) 2023-04-03
AU2021219576A1 (en) 2022-09-15
EP4103200A4 (en) 2023-08-16
KR20230019811A (ko) 2023-02-09
WO2021159187A1 (en) 2021-08-19
IL295648A (en) 2022-10-01
MX2022010066A (es) 2022-08-25
TW202143985A (zh) 2021-12-01
CN115243692A (zh) 2022-10-25

Similar Documents

Publication Publication Date Title
BR112021023457A2 (pt) Composto, uso do composto, composição, e, métodos para preparar a composição e um composto
BR112022018819A2 (pt) Vacinas contra coronavírus e métodos de uso
EA201991556A1 (ru) Ингибиторы фосфодиэстеразы и способы лечения микробной инфекции
MX2018003161A (es) Metodos para tratar infecciones por virus arenaviridae y coronaviridae.
ZA202207169B (en) Methods, compositions, and vaccines for treating a virus infection
BR112022001341A2 (pt) Inibidores de enzima
BR112017026061A2 (pt) composto, uso de um composto, e, método de tratamento de uma infecção viral
EA202091676A1 (ru) Способ лечения потери костной массы альвеолярного отростка посредством применения антител к склеростину
EA201790160A1 (ru) Способы лечения инфекций, вызываемых вирусами гепатита b и гепатита d
MX2020002883A (es) Método y composiciones para tratar la infección viral.
BR112017003663A2 (pt) composto, composição, e, método para tratamento de infecção por hiv.
EA201990010A1 (ru) Вакцина против вируса инфекционного бронхита
AU2020231934A8 (en) Compounds useful in HIV therapy
MX2023002233A (es) Compuestos fosfolipidos y usos de estos.
MX2022009176A (es) Metodo y composiciones para el tratamiento de infeccion por coronavirus.
BR112019023109A2 (pt) Composto, composição farmacêutica e método para tratar uma doença, distúrbio, síndrome ou afecção mediada por nadph oxidase em um indivíduo
WO2023122260A3 (en) Inhibitors of sars-cov-2
BR112018015629A2 (pt) ?composto, composição, método para tratar um mamífero infectado com o vírus hiv, e, proteína mutante tripla?
BR112022016177A2 (pt) Método de tratamento usando meta-arsenito
BR112021015222A2 (pt) Métodos, sistemas e kits para tratamento de doença inflamatória de alvejamento de il18r1
BR112021006388A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para tratamento de uma infecção viral em um mamífero
BR112022022515A2 (pt) Compostos de metiltionínio para uso no tratamento de covid-19
EA200870263A1 (ru) Внутривенный способ лечения вирусной инфекции
MX2022001742A (es) Metodos para prevenir el dengue y la hepatitis a.
EP4233842A3 (en) Avexitide for the treatment of hyperinsulinemic hypoglycemia

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]